This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1985 Dec;69(12):1447-8.

Amsacrine with high-dose cytarabine in acute leukemia

R Zittoun, J Bury, P Stryckmans, B Lowenberg, M Peetermans, K Y Rozendaal, C Haanen, M Kerkhofs, U Jehn, R Willemze

PMID: 3841026

Amsacrine with high-dose cytarabine in acute leukemia

R Zittoun et al. Cancer Treat Rep. 1985 Dec.

. 1985 Dec;69(12):1447-8.

Authors

R Zittoun, J Bury, P Stryckmans, B Lowenberg, M Peetermans, K Y Rozendaal, C Haanen, M Kerkhofs, U Jehn, R Willemze

PMID: 3841026

No abstract available

PubMed Disclaimer

Similar articles

Treatment of acute leukemia with amsacrine and high-dose cytarabine.
Arlin ZA, Gaddipati J, Ahmed T, Mittelman A, Friedland M, Rieber E. Arlin ZA, et al. Cancer Treat Rep. 1985 Sep;69(9):1001-2. Cancer Treat Rep. 1985. PMID: 3839713
Combination amsacrine and high-dose cytosine arabinoside in acute leukemia.
Arlin ZA. Arlin ZA. J Clin Oncol. 1985 Jan;3(1):128. J Clin Oncol. 1985. PMID: 3838101 No abstract available.
[Treatment of acute myeloid leukemia with amsacrine and high-dose cytosine arabinoside: a phase II trial].
Marit G, David B, Reiffers J, Broustet A. Marit G, et al. Bull Cancer. 1985;72(1):37-41. Bull Cancer. 1985. PMID: 3857082 French.
Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia.
Arlin ZA. Arlin ZA. Cancer Treat Rep. 1983 Nov;67(11):967-70. Cancer Treat Rep. 1983. PMID: 6357436 Review. No abstract available.
m-AMSA: a review of clinical data.
Zittoun R. Zittoun R. Eur J Cancer Clin Oncol. 1985 Jun;21(6):649-53. doi: 10.1016/0277-5379(85)90259-7. Eur J Cancer Clin Oncol. 1985. PMID: 3894030 Review. No abstract available.

See all similar articles

Cited by

Chemotherapy for relapsed and resistant acute nonlymphoblastic leukemia. Effect of ATA, an amsacrine-containing regime.
Liang R, Chan TK, Todd D. Liang R, et al. Cancer Chemother Pharmacol. 1988;21(1):68-70. doi: 10.1007/BF00262743. Cancer Chemother Pharmacol. 1988. PMID: 3342467
Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment.
Hiddemann W, Büchner T. Hiddemann W, et al. Blut. 1990 Mar;60(3):163-71. doi: 10.1007/BF01720270. Blut. 1990. PMID: 2180498 Review.
Five-day 4'-(9-acridinylamino)methanesulphon-m-anisidide and intermediate-dose cytosine arabinoside in high-risk relapsing or refractory acute myeloid leukemia.
Freund M, Giller S, Hinrichs F, Baars A, Meran J, Körfer A, Link H, Poliwoda H. Freund M, et al. J Cancer Res Clin Oncol. 1991;117(5):489-92. doi: 10.1007/BF01612772. J Cancer Res Clin Oncol. 1991. PMID: 1890142 Free PMC article. Clinical Trial.
High-dose ara-C and etoposide in refractory or relapsing acute leukemia.
Freund M, Link H, Diedrich H, LeBlanc S, Wilke HJ, Poliwoda H. Freund M, et al. Cancer Chemother Pharmacol. 1991;28(6):487-90. doi: 10.1007/BF00685829. Cancer Chemother Pharmacol. 1991. PMID: 1934254
Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine.
Mirro J Jr, Kalwinsky DK, Grier HE, Santana VM, Mason C, Murphy SB, Dahl GV. Mirro J Jr, et al. Cancer Chemother Pharmacol. 1989;24(2):123-7. doi: 10.1007/BF00263133. Cancer Chemother Pharmacol. 1989. PMID: 2731312

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Medical
- MedlinePlus Health Information